Asset
IBEZAPOLSTAT
Acurx Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04247542 | phase2 | completed | 2020-03-06 | 2023-10-03 | Acurx Pharmaceuticals Inc. | ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection |
| NCT07513285 | phase2 | recruiting | 2026-08-06 | 2027-09-29 | Acurx Pharmaceuticals Inc. | ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection |
FDA applications (0)
This company has no applications containing this asset.